27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial

Background: Patients with atopic dermatitis (AD) suffer from a multidimensional disease burden. We report clinically meaningful improvements in AD signs, symptoms, and quality of life in children treated with FDA-approved doses of dupilumab.